Sclerotherapy for hydro and spermatoceles with 99.5% Ethanol, an open clinical multicenter dose escalation study, phase 2

Region Jämtland/Härjedalen0 个研究点目标入组 110 人开始时间: 2020年10月8日最近更新: 2024年2月19日

试验速览

暂无简介。

•- Testicular hydrocele or spermatocele/epididymal cyst confirmed clinically or with ultrasound
•- Informed consent to participate
•- Symptomatic hydro or spermatocele corresponding to inconvenience that can not be ignored
•- Patients wish to undergo treatment
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 55
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 55

•- Less hat 40 years
•- Paternity wish
•- Inability to comply with discontinuation of anticoagulants as described by the Swedish society of thrombosis and hemostasis
•- Septated hydro or spermatocele on ultrasound
•- Known allergy or hypersensitivity to the study drug.
•- Mental inability, reluctance or language difficulties that make it difficult to understand the meaning of participating in the study
•- Participates in or has recently participated in a recent clinical trial (30 days).
•- Previous participation in this study.
•- Treatment with immunostimulation drugs with ATC code L01FF (pembrolizumab, ipilimumab or equivalent).

发起方

Region Jämtland/Härjedalen